AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AEON Biopharma (NYSE American: AEON) named John Bencich as Chief Financial Officer and granted inducement equity awards on April 2, 2026. The Compensation Committee approved 754,717 RSUs vesting 25% annually over four years (starting March 9, 2026) and 235,849 PSUs tied to NYSE American compliance.
PSU vesting: 25% at six months after NYSE American notifies the company of regained compliance, then 25% on each of the first three anniversaries of that date, subject to continued service and plan terms.
Positive
- 754,717 RSUs granted to CFO, vesting over four years
- 235,849 PSUs align CFO incentives with NYSE compliance milestone
Negative
- PSU vesting contingent on NYSE American compliance could delay reward realization
- Large equity grants may be dilutive depending on total outstanding share count
Details
News Market Reaction – AEON
On Apr 6, the first trading day after this news, AEON closed 2.39% above the previous close.
Data tracked by StockTitan Argus for the Apr 6 session.
Key Figures
- CFO RSU grant
- 754,717 RSUs
- Inducement award under 2025 Employment Inducement Incentive Award Plan
- CFO PSU grant
- 235,849 PSUs
- Performance-based RSUs under Inducement Plan
- RSU vesting period
- 4 years
- 25% on each annual anniversary of March 9, 2026
- Price change 24h
- -9.16%
- Move on the session before the inducement grant news
- 52-week high
- $1.45
- Price stands 38.7% below this level
- 52-week low
- $0.375
- Current price is 137.01% above this level
- Market cap
- $24,756,512
- Pre-news market capitalization
- Current price
- $0.8888
- Pre-news trading level on NYSE American
Historical Context
-
Reported 2025 results, PIPE financing and positive analytical/FDA biosimilar updates.
-
Constructive BPD Type 2a FDA feedback on analytical similarity strategy for ABP-450.
-
Appointed experienced biotech finance executive John Bencich as CFO.
-
AAN poster acceptance highlighting strong analytical comparability to Botox.
-
BPD Type 2a FDA meeting and shareholder approval enabling PIPE and note exchange.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
performance-based restricted stock units financial
nyse american regulatory
continued listing standards regulatory
vesting financial
inducement awards financial
employment inducement incentive award plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the grant of inducement awards.
The Compensation Committee approved the grant to Mr. Bencich of 754,717 restricted stock units (“RSUs”) under AEON’s 2025 Employment Inducement Incentive Award Plan (the “Inducement Plan”), which provides for the granting of equity awards to new employees of the Company. The RSUs vest over four years,
The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement or PSU agreement, as applicable, covering the grant. The awards are being granted as an inducement material to Mr. Bencich entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company seeking full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) AEON’s ability to continue to meet continued stock exchange listing standards; (ii) the Company’s ability to comply with the NYSE American approved plan to regain compliance with continued listing standards; and (iii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
laurence@newstreetir.com
Source: AEON Biopharma
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.